Yuzhen Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yuzhen Li has a total of 69 co-authors. Here are the top co-authors by number of shared publications:
- Jishu Shi
Center on Biologics Development and Evaluation, Department of Anatomy and Physiology, College of Veterinary Medicine, Kansas State University, Manhattan, KS 66506, USA
14 shared publications - Lihua Wang
Center on Biologics Development and Evaluation, Department of Anatomy and Physiology, College of Veterinary Medicine, Kansas State University, Manhattan, KS 66506, USA
14 shared publications - Rachel Madera
Center on Biologics Development and Evaluation, Department of Anatomy and Physiology, College of Veterinary Medicine, Kansas State University, Manhattan, KS 66506, USA
12 shared publications - Aidan Craig
Center on Biologics Development and Evaluation, College of Veterinary Medicine, Kansas State University, Manhattan, KS 66506, USA
6 shared publications - Danqin Li
Center on Biologics Development and Evaluation, College of Veterinary Medicine, Kansas State University, Manhattan, KS 66506, USA
6 shared publications - Nina Muro
Center on Biologics Development and Evaluation, College of Veterinary Medicine, Kansas State University, Manhattan, KS 66506, USA
6 shared publications
Latest Publications
- Open Access
Viral Vaccines as an Alternative to Antimicrobials: A Perspective from Swine Veterinarians on Challenges, Opportunities, and Future Directions
Antimicrobial resistance (AMR) is an increasing concern in food animal production. In swine herds, viral infections often lead to secondary bacterial disease and higher antimicrobial use (AMU). This study describes how U.S. swine veterinarians view the role of viral vaccines in reducing this reliance on antimicrobials. We conducted a national survey of swine practitioners and follow-up semi-structured interviews with a subset of respondents. Across participants, porcine reproductive and respiratory syndrome (PRRS), swine influenza (SIV), and rotaviral enteritis were most often named as viral diseases in urgent need of improved vaccines. These diseases cause substantial economic losses and frequently trigger AMU in commercial herds. Veterinarians reported several recurring challenges with current vaccines, including limited cross-protection against field strains, interference from maternally derived antibodies, and short duration of protection. Despite these limitations, most respondents supported vaccination as a key tool to curb AMU and indicated they would accept higher prices for clearly improved products. These findings reveal both a clear need and specific opportunities for future vaccine development to provide broader and more reliable protection, reduce AMU, and help slow the development of AMR.
Open AccessViral Vaccines as an Alternative to Antimicrobials: A Perspective from Swine Veterinarians on Challenges, Opportunities, and Future Directions
Antimicrobial resistance (AMR) is an increasing concern in food animal production. In swine herds, viral infections often lead to secondary bacterial disease and higher antimicrobial use (AMU). This study describes how U.S. swine veterinarians view the role of viral vaccines in reducing this reliance on antimicrobials. We conducted a national survey of swine practitioners and follow-up semi-structured interviews with a subset of respondents. Across participants, porcine reproductive and respiratory syndrome (PRRS), swine influenza (SIV), and rotaviral enteritis were most often named as viral diseases in urgent need of improved vaccines. These diseases cause substantial economic losses and frequently trigger AMU in commercial herds. Veterinarians reported several recurring challenges with current vaccines, including limited cross-protection against field strains, interference from maternally derived antibodies, and short duration of protection. Despite these limitations, most respondents supported vaccination as a key tool to curb AMU and indicated they would accept higher prices for clearly improved products. These findings reveal both a clear need and specific opportunities for future vaccine development to provide broader and more reliable protection, reduce AMU, and help slow the development of AMR.
- Open Access
- 4 November 2025
- Published by MDPI AG in Preprints.org
Viral Vaccines as an Alternative to Antimicrobials: A Perspective from Swine Veterinarians on Challenges, Opportunities, and Future Directions
Antimicrobial resistance (AMR) is a growing global threat driven by the overuse of antibiotics, especially in livestock. In the swine industry, viral diseases often lead to secondary bacterial infections, which increases the need for widespread antimicrobial use (AMU). This study explores the views of U.S. swine veterinarians on using viral vaccines as a way to reduce reliance on antimicrobials. Through a combination of surveys and interviews, our findings found an urgent need for better vaccines for por-cine reproductive and respiratory syndrome, swine influenza, and rotaviral enteritis. These swine diseases cause major economic losses and are a primary reason for AMU. Veterinarians identified several challenges with existing vaccines, including poor cross-protection against different strains, safety concerns, and issues with cost and availability. Despite these limitations, the study found that veterinarians are willing to invest more in improved vaccines, highlighting a strong demand for more effective tools to reduce antimicrobial use. This research identifies key opportunities for future vaccine development and veterinary strategies to create more effective approaches that protect both animal and public health.
- 4 November 2025
- Published by MDPI AG in Preprints.org
Open AccessViral Vaccines as an Alternative to Antimicrobials: A Perspective from Swine Veterinarians on Challenges, Opportunities, and Future Directions
Antimicrobial resistance (AMR) is a growing global threat driven by the overuse of antibiotics, especially in livestock. In the swine industry, viral diseases often lead to secondary bacterial infections, which increases the need for widespread antimicrobial use (AMU). This study explores the views of U.S. swine veterinarians on using viral vaccines as a way to reduce reliance on antimicrobials. Through a combination of surveys and interviews, our findings found an urgent need for better vaccines for por-cine reproductive and respiratory syndrome, swine influenza, and rotaviral enteritis. These swine diseases cause major economic losses and are a primary reason for AMU. Veterinarians identified several challenges with existing vaccines, including poor cross-protection against different strains, safety concerns, and issues with cost and availability. Despite these limitations, the study found that veterinarians are willing to invest more in improved vaccines, highlighting a strong demand for more effective tools to reduce antimicrobial use. This research identifies key opportunities for future vaccine development and veterinary strategies to create more effective approaches that protect both animal and public health.
- Open Access
Challenges and Opportunities of Bacterial Vaccines as Alternatives to Antimicrobials in Swine Health Management: Insights from U.S. Veterinarians
Antimicrobial resistance (AMR) is a significant global health concern, and the use of antibiotics in livestock, including swine production, is a major contributor. Vaccines offer a promising alternative for controlling bacterial infections in pigs, but their widespread use is often hindered by biological, economic, and practical challenges. This study surveyed U.S. swine veterinarians to identify which bacterial diseases require better vaccines and to understand the barriers to their adoption. Nineteen veterinarians with an average of 24.7 years of experience were surveyed across 21 states. The results identified Streptococcus suis, Escherichia coli, Mycoplasma hyopneumoniae, and Glaesserella parasuis as the most critical pathogens needing improved vaccines. Veterinarians anticipated significant improvements in vaccine efficacy for S. suis and E. coli during the nursery stage and expressed a willingness to pay 1.8 and 1.9 times their current prices, respectively. While expectations for M. hyo vaccine improvements were not significant, veterinarians expressed the highest willingness to pay (4.2 times the current price), citing the potential for disease eradication. This research highlights that developing effective vaccines for S. suis and E. coli should be the most urgent priority due to their significant economic impact and rising AMR concerns. However, M. hyo vaccine development holds the most economic potential due to the possibility of eradication. Our research provides a roadmap for future efforts to combat AMR in the swine industry, emphasizing key economic, policy, and educational considerations for successful vaccine implementation.
Open AccessChallenges and Opportunities of Bacterial Vaccines as Alternatives to Antimicrobials in Swine Health Management: Insights from U.S. Veterinarians
Antimicrobial resistance (AMR) is a significant global health concern, and the use of antibiotics in livestock, including swine production, is a major contributor. Vaccines offer a promising alternative for controlling bacterial infections in pigs, but their widespread use is often hindered by biological, economic, and practical challenges. This study surveyed U.S. swine veterinarians to identify which bacterial diseases require better vaccines and to understand the barriers to their adoption. Nineteen veterinarians with an average of 24.7 years of experience were surveyed across 21 states. The results identified Streptococcus suis, Escherichia coli, Mycoplasma hyopneumoniae, and Glaesserella parasuis as the most critical pathogens needing improved vaccines. Veterinarians anticipated significant improvements in vaccine efficacy for S. suis and E. coli during the nursery stage and expressed a willingness to pay 1.8 and 1.9 times their current prices, respectively. While expectations for M. hyo vaccine improvements were not significant, veterinarians expressed the highest willingness to pay (4.2 times the current price), citing the potential for disease eradication. This research highlights that developing effective vaccines for S. suis and E. coli should be the most urgent priority due to their significant economic impact and rising AMR concerns. However, M. hyo vaccine development holds the most economic potential due to the possibility of eradication. Our research provides a roadmap for future efforts to combat AMR in the swine industry, emphasizing key economic, policy, and educational considerations for successful vaccine implementation.
- Open Access
- 6 October 2025
- Published by MDPI AG in Preprints.org
Challenges and Opportunities of Bacterial Vaccines as Alternatives to Antimicrobials in Swine Health Management: Insights from U.S. Veterinarians
Antimicrobial resistance (AMR) is a significant global health concern, and the use of antibiotics in livestock, including swine production, is a major contributor. Vaccines offer a promising alternative for controlling bacterial infections in pigs, but their widespread use is often hindered by biological, economic, and practical challenges. This study surveyed U.S. swine veterinarians to identify which bacterial diseases re-quire better vaccines and to understand the barriers to their adoption. Nineteen vet-erinarians with an average of 24.7 years of experience were surveyed across 21 states. The results identified Streptococcus suis, Escherichia coli, Mycoplasma hyopneumoniae, and Glaesserella parasuis as the most critical pathogens needing improved vaccines. Veter-inarians anticipated significant improvements in vaccine efficacy for S. suis and E. coli during the nursery stage and expressed a willingness to pay 1.8 and 1.9 times their current prices, respectively. While expectations for M. hyo vaccine improvements were not significant, veterinarians expressed the highest willingness to pay (4.2 times the current price), citing the potential for disease eradication. This research highlights that developing effective vaccines for S. suis and E. coli should be the most urgent priority due to their significant economic impact and rising AMR concerns. However, M. hyo vaccine development holds the most economic potential due to the possibility of erad-ication. Our research provides a roadmap for future efforts to combat AMR in the swine industry, emphasizing key economic, policy, and educational considerations for successful vaccine implementation.
- 6 October 2025
- Published by MDPI AG in Preprints.org
Open AccessChallenges and Opportunities of Bacterial Vaccines as Alternatives to Antimicrobials in Swine Health Management: Insights from U.S. Veterinarians
Antimicrobial resistance (AMR) is a significant global health concern, and the use of antibiotics in livestock, including swine production, is a major contributor. Vaccines offer a promising alternative for controlling bacterial infections in pigs, but their widespread use is often hindered by biological, economic, and practical challenges. This study surveyed U.S. swine veterinarians to identify which bacterial diseases re-quire better vaccines and to understand the barriers to their adoption. Nineteen vet-erinarians with an average of 24.7 years of experience were surveyed across 21 states. The results identified Streptococcus suis, Escherichia coli, Mycoplasma hyopneumoniae, and Glaesserella parasuis as the most critical pathogens needing improved vaccines. Veter-inarians anticipated significant improvements in vaccine efficacy for S. suis and E. coli during the nursery stage and expressed a willingness to pay 1.8 and 1.9 times their current prices, respectively. While expectations for M. hyo vaccine improvements were not significant, veterinarians expressed the highest willingness to pay (4.2 times the current price), citing the potential for disease eradication. This research highlights that developing effective vaccines for S. suis and E. coli should be the most urgent priority due to their significant economic impact and rising AMR concerns. However, M. hyo vaccine development holds the most economic potential due to the possibility of erad-ication. Our research provides a roadmap for future efforts to combat AMR in the swine industry, emphasizing key economic, policy, and educational considerations for successful vaccine implementation.
- Open Access
- 7 March 2025
- Published by MDPI AG in Microorganisms
- Vol. 13  (3) , 615
Specific Detection of African Swine Fever Virus Variants: Novel Quadplex Real-Time PCR Assay with Internal Control
African swine fever (ASF), a highly contagious and lethal viral disease, continues to devastate the global swine industry. The emergence of ASF virus (ASFV) variants with varying genomic deletions poses significant challenges for ASF control. This study presents a novel, sensitive, and reliable quadplex real-time PCR assay for detecting ASFV variants lacking key genes (I177L, EP402R, and MGF360-14L), either individually or in combination. The assay targets conserved regions within these genes, ensuring broad coverage of diverse ASFV genotypes. A porcine beta-actin (ACTB) internal control was incorporated to minimize false-negative results. Optimization and evaluation using spike-in tests demonstrated high sensitivity, with a limit of detection (LOD) ranging from 1 to 10 plasmid copies or 0.1 TCID50 of ASFV isolates per reaction. No cross-reactivity was observed when testing serum samples from pigs infected with other common swine viruses. Further validation across a diverse panel of samples, including those from naturally ASFV-infected field pigs (n = 54), experimentally ASFV-infected pigs (n = 50), PBS-inoculated pigs (n = 50), ASFV-free field pigs (n = 100), and feral pigs (n = 6), confirmed 100% specificity. This robust assay provides a valuable tool for rapid and accurate ASF surveillance and control efforts, facilitating the timely detection and mitigation of outbreaks caused by emerging ASFV variants.
- 7 March 2025
- Published by MDPI AG in Microorganisms
- Vol. 13  (3) , 615
Open AccessSpecific Detection of African Swine Fever Virus Variants: Novel Quadplex Real-Time PCR Assay with Internal Control
African swine fever (ASF), a highly contagious and lethal viral disease, continues to devastate the global swine industry. The emergence of ASF virus (ASFV) variants with varying genomic deletions poses significant challenges for ASF control. This study presents a novel, sensitive, and reliable quadplex real-time PCR assay for detecting ASFV variants lacking key genes (I177L, EP402R, and MGF360-14L), either individually or in combination. The assay targets conserved regions within these genes, ensuring broad coverage of diverse ASFV genotypes. A porcine beta-actin (ACTB) internal control was incorporated to minimize false-negative results. Optimization and evaluation using spike-in tests demonstrated high sensitivity, with a limit of detection (LOD) ranging from 1 to 10 plasmid copies or 0.1 TCID50 of ASFV isolates per reaction. No cross-reactivity was observed when testing serum samples from pigs infected with other common swine viruses. Further validation across a diverse panel of samples, including those from naturally ASFV-infected field pigs (n = 54), experimentally ASFV-infected pigs (n = 50), PBS-inoculated pigs (n = 50), ASFV-free field pigs (n = 100), and feral pigs (n = 6), confirmed 100% specificity. This robust assay provides a valuable tool for rapid and accurate ASF surveillance and control efforts, facilitating the timely detection and mitigation of outbreaks caused by emerging ASFV variants.
- Open Access
- 13 February 2025
- Published by MDPI AG in Preprints.org
Sensitive and Specific Detection of African Swine Fever Virus Variants: A Novel Quadplex Real-Time PCR Assay with Internal Control
African swine fever (ASF), a highly contagious and lethal viral disease, continues to devastate the global swine industry. The emergence of ASF virus (ASFV) variants with varying genomic deletions poses significant challenges to ASF control. This study presents a novel, sensitive, and reliable quadplex real-time PCR assay for detecting ASFV variants lacking key genes (I177L, EP402R, and MGF360-14L), either individually or in combination. The assay targets conserved regions within these genes, ensuring broad coverage of diverse ASFV genotypes. A porcine beta-actin (ACTB) internal control was incorporated to minimize false-negative results. Optimization and evaluation using spike-in tests demonstrated high sensitivity with a limit of detection (LOD) ranging from 1-10 plasmid copies or 0.1 TCID50 of ASFV isolates per reaction. No cross-reactivity was observed when testing serum samples from pigs infected with other common swine viruses. Further validation across a diverse panel of samples, comprising those from naturally ASFV-infected field pigs (n=54), experimentally ASFV-infected pigs (n=50), PBS-inoculated pigs (n=50), ASFV-free field pigs (n=100), and feral pigs (n=6), confirmed 100% specificity. This robust assay provides a valuable tool for rapid and accurate ASF surveillance and control efforts, facilitating the timely detection and mitigation of outbreaks caused by emerging ASFV variants.
- 13 February 2025
- Published by MDPI AG in Preprints.org
Open AccessSensitive and Specific Detection of African Swine Fever Virus Variants: A Novel Quadplex Real-Time PCR Assay with Internal Control
African swine fever (ASF), a highly contagious and lethal viral disease, continues to devastate the global swine industry. The emergence of ASF virus (ASFV) variants with varying genomic deletions poses significant challenges to ASF control. This study presents a novel, sensitive, and reliable quadplex real-time PCR assay for detecting ASFV variants lacking key genes (I177L, EP402R, and MGF360-14L), either individually or in combination. The assay targets conserved regions within these genes, ensuring broad coverage of diverse ASFV genotypes. A porcine beta-actin (ACTB) internal control was incorporated to minimize false-negative results. Optimization and evaluation using spike-in tests demonstrated high sensitivity with a limit of detection (LOD) ranging from 1-10 plasmid copies or 0.1 TCID50 of ASFV isolates per reaction. No cross-reactivity was observed when testing serum samples from pigs infected with other common swine viruses. Further validation across a diverse panel of samples, comprising those from naturally ASFV-infected field pigs (n=54), experimentally ASFV-infected pigs (n=50), PBS-inoculated pigs (n=50), ASFV-free field pigs (n=100), and feral pigs (n=6), confirmed 100% specificity. This robust assay provides a valuable tool for rapid and accurate ASF surveillance and control efforts, facilitating the timely detection and mitigation of outbreaks caused by emerging ASFV variants.
- Open Access
A Non-Hemadsorbing Live-Attenuated Virus Vaccine Candidate Protects Pigs against the Contemporary Pandemic Genotype II African Swine Fever Virus
African swine fever (ASF) is a highly contagious and severe hemorrhagic transboundary swine viral disease with up to a 100% mortality rate, which leads to a tremendous socio-economic loss worldwide. The lack of safe and efficacious ASF vaccines is the greatest challenge in the prevention and control of ASF. In this study, we generated a safe and effective live-attenuated virus (LAV) vaccine candidate VNUA-ASFV-LAVL3 by serially passaging a virulent genotype II strain (VNUA-ASFV-L2) in an immortalized porcine alveolar macrophage cell line (3D4/21, 50 passages). VNUA-ASFV-LAVL3 lost its hemadsorption ability but maintained comparable growth kinetics in 3D4/21 cells to that of the parental strain. Notably, it exhibited significant attenuation of virulence in pigs across different doses (103, 104, and 105 TCID50). All vaccinated pigs remained healthy with no clinical signs of African swine fever virus (ASFV) infection throughout the 28-day observation period of immunization. VNUA-ASFV-LAVL3 was efficiently cleared from the blood at 14–17 days post-infection, even at the highest dose (105 TCID50). Importantly, the attenuation observed in vivo did not compromise the ability of VNUA-ASFV-LAVL3 to induce protective immunity. Vaccination with VNUA-ASFV-LAVL3 elicited robust humoral and cellular immune responses in pigs, achieving 100% protection against a lethal wild-type ASFV (genotype II) challenge at all tested doses (103, 104, and 105 TCID50). Furthermore, a single vaccination (104 TCID50) provided protection for up to 2 months. These findings suggest that VNUA-ASFV-LAVL3 can be utilized as a promising safe and efficacious LAV candidate against the contemporary pandemic genotype II ASFV.
Open AccessA Non-Hemadsorbing Live-Attenuated Virus Vaccine Candidate Protects Pigs against the Contemporary Pandemic Genotype II African Swine Fever Virus
African swine fever (ASF) is a highly contagious and severe hemorrhagic transboundary swine viral disease with up to a 100% mortality rate, which leads to a tremendous socio-economic loss worldwide. The lack of safe and efficacious ASF vaccines is the greatest challenge in the prevention and control of ASF. In this study, we generated a safe and effective live-attenuated virus (LAV) vaccine candidate VNUA-ASFV-LAVL3 by serially passaging a virulent genotype II strain (VNUA-ASFV-L2) in an immortalized porcine alveolar macrophage cell line (3D4/21, 50 passages). VNUA-ASFV-LAVL3 lost its hemadsorption ability but maintained comparable growth kinetics in 3D4/21 cells to that of the parental strain. Notably, it exhibited significant attenuation of virulence in pigs across different doses (103, 104, and 105 TCID50). All vaccinated pigs remained healthy with no clinical signs of African swine fever virus (ASFV) infection throughout the 28-day observation period of immunization. VNUA-ASFV-LAVL3 was efficiently cleared from the blood at 14–17 days post-infection, even at the highest dose (105 TCID50). Importantly, the attenuation observed in vivo did not compromise the ability of VNUA-ASFV-LAVL3 to induce protective immunity. Vaccination with VNUA-ASFV-LAVL3 elicited robust humoral and cellular immune responses in pigs, achieving 100% protection against a lethal wild-type ASFV (genotype II) challenge at all tested doses (103, 104, and 105 TCID50). Furthermore, a single vaccination (104 TCID50) provided protection for up to 2 months. These findings suggest that VNUA-ASFV-LAVL3 can be utilized as a promising safe and efficacious LAV candidate against the contemporary pandemic genotype II ASFV.
- Open Access
2023 International African Swine Fever Workshop: Critical Issues That Need to Be Addressed for ASF Control
The 2023 International African Swine Fever Workshop (IASFW) took place in Beijing, China, on 18–20 September 2023. It was jointly organized by the U.S.-China Center for Animal Health (USCCAH) at Kansas State University (KSU) and the Chinese Veterinary Drug Association (CVDA) and sponsored by the United States Department of Agriculture Foreign Agricultural Service (USDA-FAS), Harbin Veterinary Research Institute, and Zoetis Inc. The objective of this workshop was to provide a platform for ASF researchers around the world to unite and share their knowledge and expertise on ASF control and prevention. A total of 24 outstanding ASF research scientists and experts from 10 countries attended this meeting. The workshop included presentations on current ASF research, opportunities for scientific collaboration, and discussions of lessons and experiences learned from China/Asia, Africa, and Europe. This article summarizes the meeting highlights and presents some critical issues that need to be addressed for ASF control and prevention in the future.
Open Access2023 International African Swine Fever Workshop: Critical Issues That Need to Be Addressed for ASF Control
The 2023 International African Swine Fever Workshop (IASFW) took place in Beijing, China, on 18–20 September 2023. It was jointly organized by the U.S.-China Center for Animal Health (USCCAH) at Kansas State University (KSU) and the Chinese Veterinary Drug Association (CVDA) and sponsored by the United States Department of Agriculture Foreign Agricultural Service (USDA-FAS), Harbin Veterinary Research Institute, and Zoetis Inc. The objective of this workshop was to provide a platform for ASF researchers around the world to unite and share their knowledge and expertise on ASF control and prevention. A total of 24 outstanding ASF research scientists and experts from 10 countries attended this meeting. The workshop included presentations on current ASF research, opportunities for scientific collaboration, and discussions of lessons and experiences learned from China/Asia, Africa, and Europe. This article summarizes the meeting highlights and presents some critical issues that need to be addressed for ASF control and prevention in the future.
- Open Access
A Cell-Adapted Live-Attenuated Vaccine Candidate Protects Pigs against the Homologous Strain VNUA-ASFV-05L1, a Representative Strain of the Contemporary Pandemic African Swine Fever Virus
African swine fever (ASF) is a lethal and highly contagious transboundary animal disease with the potential for rapid international spread. Currently, there is no ASF vaccine commercially available. All infected animals must be isolated and culled immediately upon the confirmation of the presence of the virus. Studies leading to the rational development of protective ASF vaccines are urgently needed. Here, we generated a safe and efficacious live-attenuated vaccine (LAV) VNUA-ASFV-LAVL2 by serially passaging a field isolate (VNUA-ASFV-05L1, genotype II) in porcine alveolar macrophages (PAMs, 65 passages) and an immortalized porcine alveolar macrophage cell line (3D4/21, 55 passages). VNUA-ASFV-LAVL2 can efficiently replicate in both PAMs and 3D4/21 cells. It provides 100% protection, even with the low dose of 102 HAD50, to the vaccinated pigs against the challenge of contemporary pandemic ASFV field isolate. Pigs vaccinated with this LAV in a dose range of 102 to 105 HAD50 remained clinically healthy during both the 28-day observation period of immunization and the 28-day observation period of challenge. VNUA-ASFV-LAVL2 was eliminated from blood by 28 days post-inoculation (DPI), and from feces or oral fluids by 17 DPI. Although the vaccine strain in serum remained a safe and attenuated phenotype after five passages in swine, a reversion-to-virulence study using blood or tissue homogenates at peak viremia will be conducted in the future. ASFV-specific IgG antibodies and significant cellular immunity were detected in vaccinated pigs before the ASFV challenge. These results indicate that the VNUA-ASFV-LAVL2 strain is a safe and efficacious LAV against the genotype II ASFV strain responsible for current ASF outbreaks in Asia.
Open AccessA Cell-Adapted Live-Attenuated Vaccine Candidate Protects Pigs against the Homologous Strain VNUA-ASFV-05L1, a Representative Strain of the Contemporary Pandemic African Swine Fever Virus
African swine fever (ASF) is a lethal and highly contagious transboundary animal disease with the potential for rapid international spread. Currently, there is no ASF vaccine commercially available. All infected animals must be isolated and culled immediately upon the confirmation of the presence of the virus. Studies leading to the rational development of protective ASF vaccines are urgently needed. Here, we generated a safe and efficacious live-attenuated vaccine (LAV) VNUA-ASFV-LAVL2 by serially passaging a field isolate (VNUA-ASFV-05L1, genotype II) in porcine alveolar macrophages (PAMs, 65 passages) and an immortalized porcine alveolar macrophage cell line (3D4/21, 55 passages). VNUA-ASFV-LAVL2 can efficiently replicate in both PAMs and 3D4/21 cells. It provides 100% protection, even with the low dose of 102 HAD50, to the vaccinated pigs against the challenge of contemporary pandemic ASFV field isolate. Pigs vaccinated with this LAV in a dose range of 102 to 105 HAD50 remained clinically healthy during both the 28-day observation period of immunization and the 28-day observation period of challenge. VNUA-ASFV-LAVL2 was eliminated from blood by 28 days post-inoculation (DPI), and from feces or oral fluids by 17 DPI. Although the vaccine strain in serum remained a safe and attenuated phenotype after five passages in swine, a reversion-to-virulence study using blood or tissue homogenates at peak viremia will be conducted in the future. ASFV-specific IgG antibodies and significant cellular immunity were detected in vaccinated pigs before the ASFV challenge. These results indicate that the VNUA-ASFV-LAVL2 strain is a safe and efficacious LAV against the genotype II ASFV strain responsible for current ASF outbreaks in Asia.